Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30
Glaukos (NYSE: GKOS), a company specializing in ophthalmic pharmaceutical and medical technology for glaucoma, corneal disorders and retinal diseases, has scheduled its first quarter 2025 financial results release for Wednesday, April 30, 2025, after market close.
The company will host a conference call and simultaneous webcast to discuss the results at 1:30 p.m. PT (4:30 p.m. ET) on the same day. Investors can access the webcast through the company's investor relations website, while those wishing to participate in the conference call can dial 800-715-9871 (U.S.) or 646-307-1963 (International) using Conference ID 5255602.
Glaukos (NYSE: GKOS), un'azienda specializzata in tecnologia farmaceutica e medica oftalmica per il glaucoma, i disturbi corneali e le malattie retiniche, ha programmato la pubblicazione dei suoi risultati finanziari del primo trimestre 2025 per mercoledì 30 aprile 2025, dopo la chiusura del mercato.
L'azienda ospiterà una conferenza telefonica e un webcast simultaneo per discutere i risultati alle 1:30 p.m. PT (4:30 p.m. ET) dello stesso giorno. Gli investitori possono accedere al webcast tramite il sito web delle relazioni con gli investitori dell'azienda, mentre coloro che desiderano partecipare alla conferenza telefonica possono comporre il numero 800-715-9871 (USA) o 646-307-1963 (Internazionale) utilizzando l'ID Conferenza 5255602.
Glaukos (NYSE: GKOS), una empresa especializada en tecnología farmacéutica y médica oftálmica para el glaucoma, trastornos corneales y enfermedades de la retina, ha programado la publicación de sus resultados financieros del primer trimestre de 2025 para el miércoles 30 de abril de 2025, después del cierre del mercado.
La empresa llevará a cabo una conferencia telefónica y un webcast simultáneo para discutir los resultados a las 1:30 p.m. PT (4:30 p.m. ET) del mismo día. Los inversores pueden acceder al webcast a través del sitio web de relaciones con inversores de la empresa, mientras que aquellos que deseen participar en la conferencia telefónica pueden marcar el 800-715-9871 (EE. UU.) o el 646-307-1963 (Internacional) utilizando el ID de Conferencia 5255602.
Glaukos (NYSE: GKOS), 녹내장, 각막 질환 및 망막 질환을 위한 안과 제약 및 의료 기술에 특화된 회사는 2025년 1분기 재무 결과 발표를 2025년 4월 30일 수요일, 시장 종료 후로 예정하고 있습니다.
회사는 같은 날 오후 1시 30분 PT (오후 4시 30분 ET)에 결과를 논의하기 위한 전화 회의 및 동시 웹캐스트를 개최할 것입니다. 투자자들은 회사의 투자자 관계 웹사이트를 통해 웹캐스트에 접근할 수 있으며, 전화 회의에 참여하길 원하는 분들은 800-715-9871(미국) 또는 646-307-1963(국제)로 전화하여 회의 ID 5255602를 사용하면 됩니다.
Glaukos (NYSE: GKOS), une entreprise spécialisée dans la technologie pharmaceutique et médicale ophtalmique pour le glaucome, les troubles de la cornée et les maladies rétiniennes, a prévu la publication de ses résultats financiers du premier trimestre 2025 pour le mercredi 30 avril 2025, après la fermeture du marché.
L'entreprise organisera une conférence téléphonique et un webinaire simultané pour discuter des résultats à 13h30 PT (16h30 ET) le même jour. Les investisseurs peuvent accéder au webinaire via le site web des relations investisseurs de l'entreprise, tandis que ceux souhaitant participer à la conférence téléphonique peuvent composer le 800-715-9871 (États-Unis) ou le 646-307-1963 (International) en utilisant l'ID de conférence 5255602.
Glaukos (NYSE: GKOS), ein Unternehmen, das sich auf ophthalmologische Arzneimittel und Medizintechnologie für Glaukom, Hornhauterkrankungen und Netzhauterkrankungen spezialisiert hat, hat die Veröffentlichung seiner Finanzergebnisse für das erste Quartal 2025 für Mittwoch, den 30. April 2025, nach Börsenschluss angesetzt.
Das Unternehmen wird am selben Tag um 13:30 Uhr PT (16:30 Uhr ET) eine Telefonkonferenz und einen gleichzeitigen Webcast abhalten, um die Ergebnisse zu besprechen. Investoren können über die Website für Investor Relations des Unternehmens auf den Webcast zugreifen, während diejenigen, die an der Telefonkonferenz teilnehmen möchten, die Nummer 800-715-9871 (USA) oder 646-307-1963 (International) mit der Konferenz-ID 5255602 wählen können.
- None.
- None.
Conference Call and Webcast Scheduled for 1:30 p.m. PT
A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rare corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250409019125/en/
Chris Lewis
Vice President, Investor Relations and Corporate Affairs
(949) 481-0510
clewis@glaukos.com
Source: Glaukos Corporation
FAQ
When will Glaukos (GKOS) release Q1 2025 earnings?
What time is the Glaukos (GKOS) Q1 2025 earnings call?
How can investors access the Glaukos (GKOS) Q1 2025 earnings call?
Will there be a replay available for Glaukos (GKOS) Q1 2025 earnings call?
